TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02606032
Drug: Terbinafine
Normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active comparator
Study: NCT00932477
Drug: Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 to 2 drops into each eye three times per day
Study: NCT00932477
Drug: Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 to 2 drops into each eye three times per day
Study: NCT00932477
Drug: Glycerin and Polysorbate 80 based artificial tear
Normalized name: glycerin / polysorbate 80
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 drops into each eye three times per day
Study: NCT00156182
Drug: Asoprisnil
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg Tablet, oral Daily for 6 months
Study: NCT04113005
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment. Additionally, CTCs will be collected before and after Desmopressin/Docetaxel treatment to evaluate therapeutic efficacy.
Study: NCT02071914
Drug: CT-P27
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza A treatment drug.
Study: NCT03978520
Drug: Elsubrutinib
Normalized name: Elsubrutinib
DrugBank: Elsubrutinib (DB18850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule; Oral
Study: NCT01034995
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: encapsulated tablets~Route of administration: oral
Study: NCT00171860
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02227238
Drug: DTG
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DTG is supplied as 50 mg tablets
Study: NCT01632306
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine administered IV
Study: NCT01632306
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel administered IV
Study: NCT00865020
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 150 mg tablets taken orally daily. 1 tablet for the first two weeks followed by 2 tablets for 10 weeks.
Study: NCT00865020
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 40 mg capsules taken orally daily. 1 capsule the first 2 weeks followed by 2 capsules for 10 weeks.
Study: NCT00865020
Drug: Placebo to Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to Aliskiren tablets taken orally daily. 1 Tablet for the first 2 weeks and 2 tablets during the no treatment (withdrawal) week.
Study: NCT00865020
Drug: Placebo to Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to Telmisartan capsule taken orally daily. 1 capsule for the first 2 weeks and 2 capsules during the no treatment (withdrawal) week.
Study: NCT01223755
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be given SRL for one year starting at the oral daily dose of 3 mg, with periodical whole blood level measurements. The daily dose will be adjusted to keep SRL concentration within 5-10 ng/ml. Drug levels will be assessed at day 7 after starting treatment and every two weeks for the first month. Subsequently SRL concentrations will be monitored at monthly intervals (or at least 5 days after drug dose adjustments) until the end of the treatment period.
Study: NCT01448200
Drug: PPI-668
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT00667615
Drug: rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
Study: NCT00974987
Drug: TMZ(temozolomide)
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75mg/m2 for day1-12. After XRT, repeat the cycle of 150-200mg/m2 for 5 days and cessation for 23 days.
Study: NCT03978520
Drug: Placebo for elsubrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule; Oral
Study: NCT02284139
Drug: Arm EGF ointment 1ppm
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day
Study: NCT02284139
Drug: Arm EGF ointment 20 ppm
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day
Study: NCT02734511
Drug: sedation with propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
Study: NCT03978520
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Film-coated tablet; Oral
Study: NCT03978520
Drug: Placebo for upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Film-coated tablet; Oral
Study: NCT00867360
Drug: Mifepristone (RU-486)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02818569
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral form
Study: NCT01175330
Drug: Omega-3 fish oil emulsion (Omegaven)
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
Study: NCT01175330
Drug: Intralipid
Normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
Study: NCT01451541
Drug: Ciclesonide nasal aerosol 37 mcg
Normalized name: Ciclesonide Nasal Aerosol
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
Study: NCT01451541
Drug: ciclesonide nasal aerosol 74 mcg
Normalized name: Ciclesonide Nasal Aerosol
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
Study: NCT04604938
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of losartan (50 mg) (oral)
Study: NCT00913029
Drug: latanoprost/timolol
Normalized name: Dorzolamide/Latanoprost/Timolol Ophthalmic
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination latanoprost/timolol
Study: NCT01783678
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir 400 mg tablet administered orally once daily
Study: NCT01783678
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT00006388
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01909115
Drug: 1000 IU of Vitamin D3
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU of Vitamin D will be administered in capsule form, once daily.
Study: NCT01909115
Drug: 4000 IU of Vitamin D3
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU of Vitamin D will be administered in capsule form, once daily.
Study: NCT03234309
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00691470
Drug: ATI-5923
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Adjusted based on INR.
Study: NCT00691470
Drug: Coumadin (warfarin)
Normalized name: warfarin Oral Tablet [Coumadin]
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose adjusted based on INR.
Study: NCT03541252
Drug: AFL-assisted cisplatin+5-FU
Normalized name: 5-FU
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive AFL-assisted cisplatin+5-FU as a treatment for their BCC. In brief, treatment areas consisting of tumors and a 5 mm margin will undergo CO2 laser exposure followed by 60 min topical application of a marketed and commercially available IV cisplatin solution (0.1%) After removal of cisplatin, a commercially distributed 5-FU cream (5%) will be applied to the treatment area at a dose of 0.125 ml per cm2 and left under occlusion. After skin evaluations on Day 1 and 5 after treatment, the same 5-FU dose will be applied, again left under occlusion. In total, 5-FU will remain on the skin for 7 days after AFL treatment whereafter it will be washed off. An additional repeat AFL-cisplatin+5-FU treatment on Day 30 will be offered if tumors persist, based on clinical evaluation and imaging on Day 30.
Study: NCT06239129
Drug: Initiation of specific medications
Normalized name: salicylic acid Medicated Patch [Compound W brand of salicylic acid]
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple therapies studied within this database
Study: NCT02007603
Drug: Administration of Amoxicillin / clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive amoxicillin / clavulanic acid due to clinical necessity
Study: NCT02007603
Drug: Ampicillin / sulbactam
Normalized name: ampicillin / sulbactam
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive ampicillin / sulbactam due to clinical necessity
Study: NCT00410488
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg IV by rapid administration on day 0 (for patients with small cell histology).~For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only.
Study: NCT01072344
Drug: Chamomile (Matricaria recutita)
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg 3 times daily
Study: NCT01002092
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day
Study: NCT01135589
Drug: Micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.v.
Study: NCT02736019
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women will receive oral Tramadol 100 mg 2 hours before the procedure
Study: NCT00188630
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03269344
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin is an anticonvulsant and has been used to manage neuropathic pain and is FDA-approved for the treatment of post-herpetic neuralgia and partial onset seizures
Study: NCT00305578
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memantine will be given orally. Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.
Study: NCT00435968
Drug: CVT E002 (Cold-fX)
Normalized name: CVT-6883
DrugBank: CVT-6883 (DB05936)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01954693
Drug: Everolimus (RAD001)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg daily administered for 6 months as two oral 2.5 mg tablets once daily
Study: NCT04269395
Drug: MAL Cream
Normalized name: PLO Transdermal Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No intervention will be administered as a part of this study. Participants who received MAL cream in RD.06.SPR.112199 study will be rolled over in the study.
Study: NCT00524056
Drug: Carisbamate
Normalized name: carisbamate
DrugBank: Carisbamate (DB12338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 100 mg tablets twice per day
Study: NCT00159432
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00159432
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01677247
Drug: Group I (Test) : Glimepiride 4 mg tablet of PT Dexa Medica
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
Study: NCT01677247
Drug: Group II (Reference) : glimepiride (Amaryl) 4 mg tablet of PT Sanofi Aventis
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
Study: NCT03248726
Drug: Polyethylene glycol and bisacodyl
Normalized name: Polyethylene Glycol
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention: Take 3 tablets (15mg) of stimulant laxatives Dulcolax® (bisacodyl) at 10pm the day before examination. Take two pack of osmotic laxative Klean-prep® powder (Polyethylene glycol) mixed with 2000ml water at 5am on the morning of examination.
Study: NCT00000159
Drug: Sorbinil
Normalized name: Sorbinil
DrugBank: Sorbinil (DB02712)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03149900
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See Arm Description
Study: NCT03248726
Drug: Split-dose polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take two pack of Klean-prep® powder mixed with 2000ml water at 6pm before the day of examination, and take another two pack of osmotic laxative Klean-prep® powder mixed with 2000ml water at 5am on the examination day.
Study: NCT01243983
Drug: LX211
Normalized name: Lixisenatide
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~* Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~* Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks
Study: NCT02542254
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
Study: NCT02542254
Drug: Ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 micrograms ipratropium administered using a pMDI
Study: NCT02542254
Drug: Ipratropium matched placebo
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo pMDI
Study: NCT03346902
Drug: EB-001
Normalized name: ANEB-001
DrugBank: ANEB-001 (DB18908)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of EB-001 into area of scarring (forehead)
Study: NCT03346902
Drug: 0.9% Sodium Chloride Injection
Normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of Saline into area of scarring (forehead)
Study: NCT03069963
Drug: Z0063
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: chewable tablets~Route of administration: oral
Study: NCT03069963
Drug: Gaviscon
Normalized name: Gaviscon
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: chewable tablets~Route of administration: oral
Study: NCT00996697
Drug: Budesonide/formoterol and tiotropium
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Symbicort 200/2, 2puff bid plus tiotropium 18mcg/day
Study: NCT00996697
Drug: Budesonide/formoterol and placebo
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Symbicort 200/6 2puff bid and placebo
Study: NCT03196284
Drug: Concizumab
Normalized name: concizumab
DrugBank: Concizumab (DB12820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase
Study: NCT03196284
Drug: Eptacog alfa
Normalized name: Eptacog alfa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
Study: NCT01139762
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 milligrams (mg) administered orally, once daily for 26 weeks
Study: NCT01139762
Drug: Finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg administered orally, once daily for 26 weeks
Study: NCT03895879
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab sc (162 mg) once every 2 weeks
Study: NCT03895879
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab sc (162 mg) once every week
Study: NCT00410488
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV piggyback (IVPB) daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy.
Study: NCT03054610
Drug: Betamethason Sodium Phosphate
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03054610
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03961828
Drug: Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]
Normalized name: ledipasvir 90 MG / sofosbuvir 400 MG [Harvoni]
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The fifty (50) thalassemic children infected with HCV received the new direct-acting antiviral therapy in the form of Ledipasvir (90 mg)/Sofosbuvir (400 mg); (Harvoni) as a single oral tablet /day for 12 weeks Follow up of these patients was performed for 24 weeks. Re-evaluation of these children after 24 weeks from initiation of Ledipasvir/Sofosbuvir treatment was performed by repeating clinical assessment, Fibroscan of liver , laboratory investigations including quantitative HCV RNA by PCR and serum hyaluronic acid measurement.
Study: NCT03322878
Drug: Magnesium SO4
Normalized name: MAGNESIUM SO4 1MEQ/ML INJ
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
Study: NCT02471183
Drug: Selexipag
Normalized name: Selexipag
DrugBank: Selexipag (DB11362)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
Study: NCT00469885
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For reduction
Study: NCT01538160
Drug: recombinant factor VIIa
Normalized name: Human recombinant factor VIIa variant (P10Q, K32E, T106N, V253N), desialylated
DrugBank: CT-001 (DB18284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 20ug/kg of recombinant factor VIIa along with tranexamic acid of 4 gram a day for 7 days following surgery
Study: NCT00008060
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00008060
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00405860
Drug: CellCept (mycophenolate mofetil)
Normalized name: Cellcept
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02997176
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral doses of talazoparib 0.5 mg